Audience: Individuals Performing COVID-19 Testing
Level: Laboratory Alert
After December 31, 2021, CDC will withdraw the request to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of the CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel, the assay first introduced in February 2020 for detection of SARS-CoV-2 only. CDC is providing this advance notice for clinical laboratories to have adequate time to select and implement one of the many FDA-authorized alternatives.
Visit the FDA website for a list of authorized COVID-19 diagnostic methods. For a summary of the performance of FDA-authorized molecular methods with an FDA reference panel, visit this page.
In preparation for this change, CDC recommends clinical laboratories and testing sites that have been using the CDC 2019-nCoV RT-PCR assay select and begin their transition to another FDA-authorized COVID-19 test.
CDC encourages laboratories to consider adoption of a multiplexed method that can facilitate detection and differentiation of SARS-CoV-2 and influenza viruses.
Such assays can facilitate continued testing for both influenza and SARS-CoV-2 and can save both time and resources as we head into influenza season. Laboratories and testing sites should validate and verify their selected assay within their facility before beginning clinical testing.
CDC press release /21Jul2021
村松社長
最新記事 by 村松社長 (全て見る)
- 穏やかな国民性の国でもストが継続されそう(スオミの国) - 2024年3月29日
- 欧州の観光立国イタリアでもテロ警戒が最高レベルになりましたね - 2024年3月28日
- スト応援しています! - 2024年3月28日
- 欧州の空のインフラ覇権者は実施上、【英】『英国航空』、【仏】フランス航空、【独】ドイツ航空が独占! - 2024年3月28日
- 安全を担保するには、相当の覚悟と強い信念が要る - 2024年3月27日